TransCelerate has created an initiative to facilitate the industry's movement toward optimal use of electronic data sources for clinical research. Although guidance and standards have been in place for some time, gaps remain. Consequently, transcription among electronic systems continues to be the norm. In the initial phase of the eSource Initiative, TransCelerate is developing a thorough understanding of the current landscape. As a preliminary step in this process, the TransCelerate eSource Initiative published Optimizing the Use of Electronic Data Sources in Clinical Trials: The Landscape Part I, which provided insight into sponsor company eSource activities and the environment affecting eSource adoption based on input from TransCelerate member companies, standards organizations, and regulatory authorities. For Part II (this article), TransCelerate surveyed technology companies, including CROs providing technology, to better understand capabilities available today, plans for eSource, and perceived barriers to greater adoption. This information is a vital input that will help shape upcoming TransCelerate proposals for best practices for industry utilization of electronic data collection tools and methods. It is clear from the survey results that the technologies needed to support the various eSource modalities are mature. However, the approach to implementing eSource is fragmented. Greater collaboration is needed not only within the pharmaceutical industry but across industries that include health care and technology. The industry must reach common understandings about novel endpoints, data standards, system validation, and related issues. While technology in itself is not a significant barrier to eSource implementation, interoperability among systems is an enormous challenge to establishing a complete end-to-end electronic health care and research ecosystem. The TransCelerate eSource Initiative will continue to evaluate the technology, regulatory environment, data standards, and health care landscape to support the goal of improving global clinical science and global clinical trial execution. Forthcoming publications will focus on future vision and demonstration projects.
Introduction
Technology supporting the collection, validation, analysis, and submission of clinical data for global drug approvals has not kept pace with advances in other industries. Improvement of global clinical science and trial execution for the key stakeholders-patients, sites, and sponsors-is at the heart of the work of the TransCelerate eSource team. Collaboration within and outside of TransCelerate has been an important step to understand what is achievable today and what must be done to maximize use of electronic data to support new drug submissions. Many TransCelerate eSource team members have noted that most individuals today have extensive functional knowledge. However, cross-functional teams with knowledge across technical, regulatory, data standards, data privacy, data security, site, and patient areas are critical to success.
The first paper published by the TransCelerate Initiative (November 2016, TIRS) 1 addressed the sponsor perspective on eSource utilization and challenges based on Spring 2016 survey responses from TransCelerate member companies. This paper assesses technology capabilities currently available from vendors in the clinical research space.
It is important to re-emphasize that there is no standard industry definition of eSource. For the purposes of the Trans-Celerate eSource Initiative and the content of this paper, US Food and Drug Administration's (FDA's) interpretation of eSource data was adopted: "data initially recorded in electronic format." 2 FDA has noted that eSource data " . . . can include information in original records and certified copies of original records of clinical findings, observations, or other activities captured prior to or during a clinical investigation used for reconstructing and evaluating the investigation." 2 Other terms will also require a common definition. For example, interoperability is referred to by the Institute of Electrical and Electronics Engineers (IEEE) in basic terms as "the ability of a system or a product to work with other systems or products without special effort on the part of the customer. Interoperability is made possible by the implementation of standards." 3 FDA views interoperability as a concept that will support the foundation of a next-generation system for evidence generation. 4 However, interoperability from a practical perspective is currently difficult to achieve because of many factors such as inconsistent standards, varying data models, semantics, and the risk that deriving data from human subjects poses to the security and privacy of individual health information.
This paper summarizes the TransCelerate eSource Initiative's work to survey external sources and stakeholders regarding the current technology landscape, reports the results of such work, and represents the perspective provided by the TransCelerate eSource Initiative on current considerations related to the technology landscape. Technology-based capabilities are not only about the acceptance of technology that can make the clinical trial process more efficient and add value for patients and sites, but also include the due diligence that demonstrates how systems can conform to accepted data standards, be validated within a regulated environment, and adhere to data security methods that protect the rights of subjects and the institutions.
Methods
The team took a multifaceted approach to investigating current technical capabilities. This included working group discussions that contributed expertise to survey design, a literature search, along with a review of survey and literature output, and discussions with standards development organizations and technology industry representatives.
Survey
The eSource Initiative team surveyed technology companies, including clinical research organizations that provide software and/or hardware, to obtain information on the current state of technology available to support eSource. Survey questions addressed product maturity, geographical use, modalities, suitability for various types of trials, interoperability experience, data security and privacy concerns, regulatory challenges, and change management issues that may impede uptake.
Surveys were distributed to companies identified through team members, external organizations, and Internet search. Surveys were also made available on transceleratebiophar mainc.com and promoted via social media (eg, LinkedIn and Twitter) to allow additional companies to respond. Companies responded to the survey questions associated with their product(s). Responses were collected by a third party, and data were aggregated for analysis on an anonymous basis.
Literature Review
A literature review was conducted using PubMed with English keywords and database-specific terms identified by the members of the eSource Initiative team and by collection of relevant health authority guidance documents. The literature review used the following search terms and appropriate synonyms: electronic CRF (eCRF), electronic source data, digital health record, DDC (direct data capture), electronic data capture (EDC), remote data capture, paperless trial, electronic clinical outcome assessment, electronic patient-reported outcome, electronic diary, apps, patient engagement, compliance, adherence, medical application, electronic data transfer, data mapping, EHR (electronic health records), wearables, interoperability, and meaningful use. Additional publications were collected from gray literature sources (eg, White papers) because of the current nature of many of these topics. A search of popular and technology media was also conducted using the same search terms.
Relevant criteria from abstracts and selected full-text articles included publication dates within the past 5 years. The literature review focused on articles of general applicability to eSource rather than focusing on a specific topic area. The literature review and technology survey completion were performed in parallel; both the literature review search terms and the survey questions were based on prior team discussions and research.
Stakeholder Discussions
In recognition of the importance of alignment and connectivity, discussions have been ongoing with Clinical Data Interchange Standards Consortium (CDISC) and Health Level Seven International (HL7) with respect to opportunities to engage in broader collaboration with a variety of eSource stakeholders. CDISC has organized the eSource Stakeholder's Group, a separate working group that has communicated with the TransCelerate eSource Initiative. HL7 opportunities included exploring the prospect of engaging in projects such as Project Argonaut and HL7 Fast Healthcare Interoperability Resources (FHIR) connectathons, which involve multiple technology and site participants. 5 Additionally, there have been discussions directly with HL7 about beneficial use cases that can be developed for connectathons.
eSource-related topics were also discussed with technology companies offering different types of eSource solutions and academic medical centers. Their input helped inform the questions asked in the eSource surveys. Discussions were focused on general eSource topics rather than vendor-specific technologies or products.
Results

Interviews
TransCelerate eSource Initiative members met with several institutions and eSource companies in order to discuss the technology landscape and willingness to respond to a technology survey. The meetings helped members shape the technology survey. The team also gathered some information not incorporated in the survey; nevertheless, it is relevant to eSource. Some of the key takeaways are presented below.
Several of the interviewees helped to confirm that the eSource landscape is fragmented. There are a variety of approaches to eSource in use today. For example, Interconnecting the Healthcare Enterprise's (IHE's) Retrieve Form for Data Capture (RFD) is available to be used to capture research data from within the EHR system. 6 DDC systems are being used to capture data. Vendors have developed integrations to capture data directly from instruments and laboratory information management systems (LIMS). They are continuing to develop more integrations that may not be broadly extended to multiple different products and technologies. Vendors are working to extract data from EHR systems; some are developing study-specific integrations to accomplish this. Some vendors have taken the approach to build a hub that accepts many data domains and formats, and transforms those data into standard outputs that sponsors can more readily accept, saving sponsors from processing multiple data formats from a variety of sources. There is also a trend toward collecting eSource data and putting it in the EDC system or another data repository: a central hub to collect data from various sources and perform data analysis.
Interviewees also supported the notion that eSource today is not done in a widely scalable fashion:
Integration of EHR to EDC, while still a challenging undertaking, has been successfully accomplished in academic research institutions where both the EHR and EDC systems are under the control of the institution. Vendors shared successes initiating eSource data collection in phase 1 studies, where they refine tools and processes to better enable them to support phase 2 and 3 trials. Vendors communicated that they are actively interested in bringing EHR data into their EDC systems. Institutions are beginning to make use of HL7's FHIR standard as a means of accessing data from EHR systems, or for application development. The EHR data they are transferring is somewhat limited (eg, demographic or concomitant medication data). Using data from EHR systems is not universal and may work better for certain studies or phases. Standards are important as evidenced by the approach to build hubs to collect and transform data to a common format, and by various standards such as RFD and FHIR. Several interviewees also suggested that more collaboration is needed among sponsors, sites, standards development organizations. and vendors in the health care and clinical research markets.
Finally, despite objective evidence that shows eSource systems can reduce errors and capture quality data more quickly along with anecdotal evidence that it can reduce cost, vendors noted clients and regulators frequently express their general discomfort with capturing data directly into EDC systems, often citing feedback and concerns about data privacy, data custody, and data security. 7
Survey and Literature Review
Overall, 29 companies responded to the survey. Companies self-selected the category of survey(s) that they completed based on their product lines.
The complete breakdown of survey responses was as follows:
3 companies responded to the Non-CRF section of the survey. 13 companies responded to the DDC section of the survey. 13 companies responded to the Devices and Apps section of the survey. In some cases, not all questions were answered, but all collected data were compiled.
Data and Subject Rights Protection
Systems used in the conduct of clinical trials must adhere to governing regulations, ensure subject privacy, and maintain data integrity. Companies were asked to provide steps taken to protect the data collected. Below are key strategies from the survey:
Utilization of modern data encryption technology, encrypting data at rest and during transmission. Use of a secure data center (or secure data environment) that meets the latest industry standards.
Compliance with industry security and health authority requirements. Requirement for log-in credentials to access data and synchronize with secure cloud. Limit access to the server by system administrators only. Regular backup of data and storage off-site. Deidentification of protected health information prior to submission inclusive of redaction of patient signatures where present. Assurance that SOPs are in place to codify processes to protect subject rights. Assurance that privacy and Good Clinical Practices training is in place. Services adhere to a stringent cloud readiness process, with technical and security reviews and penetration testing.
Non-CRF Data
Non-CRF data are defined as data not collected on CRFs such as central laboratory data, imaging, ECG, randomization, and drug accountability data, etc. and integrate with the system capturing data such as LIMS for central laboratories and Interactive Response Technology for randomization. 1 Non-CRF data are the most mature among industry, although many challenges remain.
Global Deployment and Clinical Trial Use
All 3 companies that participated in the Non-CRF survey have launched their products in Canada, Europe, and US for clinical trials. Two of 3 companies have 100þ clinical trials that currently use their products. One of 2 companies had data from their product included in health authority submissions for approval of a drug and had a regulatory inspection performed. In terms of standards, all 3 companies use several types of guidance such as Controlled Vocabulary, Study Data Tabulation Model (SDTM), Clinical Data Acquisition Standards Harmonization (CDASH) and Analysis Data Model (ADaM).
Exchanging and Reconciling Data
All respondents indicated data are provided to clients via File Transfer Protocol (FTP). Two of 3 companies provide access to clients via portal or website and Application Program Interface (API). One company responded that they provide physical media such as DVD, storage device, etc. All 3 companies responded that they facilitate reconciling/cleaning data via a visualization tool and export features (eg, Excel Spreadsheets, SAS data sets). Two of 3 companies reported integration with other systems/servers (eg, SAS). Two companies listed that they see clients mainly perform reconciliation for Demography and Disposition data points.
Client Feedback and Future Enhancements
Companies that provided feedback shared information on their product and what was done related to their product development roadmap. Comments from clients included positive input on how the data were tracked and reporting capabilities. One company received comments regarding the dedication and flexibility of their staff and ease of transforming raw data for analysis. Challenges and/or barriers encountered by clients included "data sources' lack of readiness to provide data in meaningful ways" and "software versioning issues." Description of product development included establishing standards for data transfers with various labs, better integration with visualization tools, and enhancing "existing integration capabilities to import EHR and relevant healthcare data and enhance the platform to seamlessly work with devices and app data in support of mobile health (mHealth) trials." Two of 3 responding companies plan to enhance their integration capabilities with other platforms.
Direct Data Capture
The DDC surveys and literature reviews focus on technology solutions that enable direct entry of clinical data by site staff without a source document. 1 The goals of these solutions include, but are not limited to, eliminating unnecessary duplication of data, reducing the possibility for transcription errors, eliminating transcription of source data into an eCRF, promoting real-time access for data review and monitoring, collecting higher-quality data that enable better decision making, and optimizing site and sponsor resources.
In the previously published TransCelerate article "Optimizing the Use of Electronic Data Sources in Clinical Trials: The Landscape Part I," 7 of 10 responding companies reported significant challenges that would directly affect future decisions, including site-specific considerations (i.e., training), infrastructure components, the time needed for study set-up, and overall expense of the software or platform utilized. 1 Technology surveys aim to provide additional insight into available solutions for efficient data collection during subject visits, managing site workflow, and minimizing transcription of data. Suggestions to prepare for optimal use of eSource technologies and gain valuable insights into DDC capabilities are shown in the responses presented below.
Global Deployment and Clinical Trial Use
The survey regarding direct data capture elicited responses from 13 companies that have deployed their products in major markets around the world, including Europe (10), the United States (13), Canada (10), Japan (9), China (5), and South America (6). Twelve respondents indicated that their products were used to support clinical trials. Companies reported conducting trials across 14 therapeutic areas, across all phases, with 6 companies reporting deployment in over 100 trials each. Although pharmaceutical companies were the largest users of DDC technology (11/12), academic medical centers (8/12), private research organizations (9/12), government organizations (4/12), medical device companies (1/12), and global health foundations (1/12) were also reported.
Data included for health authority submissions were reported by 9 of 13 companies; countries or regions where those submissions occurred are represented in Figure 1 . Eight companies reported undergoing regulatory inspection; feedback was received from EMA, FDA, and Health Canada. One company indicated that feedback received resulted in changes to their product, but that feedback was not shared. Vendor companies reported a variety of ways of providing contemporaneous and continuous access to data, including the ability to display data in dashboards and through secure cloud-based solutions available 24/7.
Standards and Technical Considerations
Several questions were asked with respect to validation, use of data standards, and data transfer considerations. Validation and adherence to 21 CFR, Part 11, were reported as Yes by 12/13 companies, with 1 respondent indicating unknown ( Figure 2 ).
Four of 13 respondents require companion technology in addition to a computer (eg, smartphone or a mobile app) to enable direct data capture. Data exchange is handled through a number of mechanisms; all companies reported using an API (Figure 3 ). Methods for providing data to the client at the end of the study are shown in Figure 4 . The capability to integrate with other vendors' systems is illustrated in Figure 5 . A particular concern when transferring data is risk of data loss. None of the products in use at the time of the survey had ever experienced data loss, and redundancies and backups were expressed as risk mitigations.
While all responding DDC vendors (n ¼ 13) indicated that their solutions are optimized for handheld devices (eg, tablets, smart phones) and offer workflow capability to optimize data collection, only 54.5% (6 of 11 responses) indicated that their product allows clinicians to enter visit notes that are visible only to the clinician and not sent to the sponsor. Seven of 13 respondents indicated their product would function off-line. Figure 6 describes how devices are managed. Some of the future considerations included point-of-care data collections such as video, voice and picture, development of integration points for real-world evidence, eConsent, other EDC tools, and full integration with EHRs.
Success Considerations
Eleven of 13 companies indicated they received feedback that their product worked particularly well. Challenges and barriers encountered with DDC products are listed in Figure 7 . Nine of 13 companies reported end users took less than 1 hour to learn their product. A number of attributes contributed to study success are represented in Figure 8 .
Return on Investments
Return on investment (ROI) for technology used in DDC can be measured in a number of ways. Figure 9 illustrates measures vendors use for ROI.
Devices and Apps
Devices and Apps include "the use of mobile and wireless devices (e.g., wearable technology) to improve health outcomes, healthcare services and health research." 1, 8 Based on our literature review, key themes are summarized below:
Improvements in data quality, patient engagement, trial adherence, and safety signal detection are stated benefits of Devices and Apps. 9 Key challenges that limit use from a clinical trial perspective include common definition of terminology; part 11 compliance; system interoperability/integration; data security; and a lack of validation methods, data standards, and approved novel endpoints. 10, 11 The technology survey included responses from 13 companies that develop mobile apps and wearable devices for clinical research. Eleven respondents indicated that their products have been used globally to support clinical trials. The summary of their trial experience is illustrated in Figure 10 .
Pharmaceutical companies were reported (11/11) as the primary customers for these products while academic medical centers (8/12), private research organizations (6/12), Figure 6 . Describing device management (eg, provisioning of devices, replacement of lost/damaged/malfunctioning devices). *Other responses included "for different types of products and studies, different type of device management is used" (n ¼ 1) and "see below" (n ¼ 1). Figure 8 . Factors contributing to successful studies with clients. *Other comments included "see answer to previous question" (n ¼ 1) and "knowledge of their protocols and ability to make and stand by their own eClinical protocol-dependent decisions despite sponsor personnel turnover and ever-changing protocols" (n ¼ 1). government organizations (3/12), and medical device companies (1/12) were also reported.
Challenges/Barriers
Number of Vendors
ROI Measures
Number of Vendors Reporting
Together, respondents reported 900þ trials (phase I-IV) across broad therapeutic areas (including 400þ trials in unknown therapeutic areas) with significant activity in the areas of oncology, neuroscience, and respiratory ( Figure 11 ). Despite the perceived challenges associated with Devices and Apps, nearly 300 phase II-III trials have collected data using Devices and Apps (data not shown), with the highest adoption coming from neuroscience. With regard to system validation for Devices and Apps, 9 of 13 respondents self-declared 21 CFR Part 11 compliance of their validated product(s). Respondents also reported that their data have been used for primary endpoint (11/12), secondary endpoint (10/13), exploratory endpoint (9/12), and safety endpoint (7/12), particularly in neuroscience studies. Seven respondents indicated that data were included in regulatory submission in the following countries and regions: USA (7), Europe (7) , Canada (3), Japan (2), China (1), South America (1), and Russia (1).
From the system integration perspective, the majority of respondents indicated that their products can be integrated with other eSource systems, including other Devices and Apps (9/12), Direct Data Capture (9/12), Electronic Data Capture (9/12), Electronic Health Record (4/12), Non-CRF Data (3/12), and reimbursement/payment systems (1/12). A variety of file transfer mechanisms were employed to deliver data to a sponsor at the end of study ( Figure 12 ). The file formats include primarily comma-separated value, Microsoft Excel, and SAS. Five of 13 respondents reported regulatory inspection; no feedback was shared. Only 2 of 12 respondents reported experience with data loss (<5%).
Device and App companies also reported providing a variety of data services including data archiving (8/11), quality control/data cleaning (6/11), mapping to CDISC standards (6/11), statistical analysis (4/11), algorithm development (4/11), and data interpretation (3/11). Additional data standards supported included HL7, ODM, SDTM, and CDASH.
Consistent with our literature review, our technology survey identified key benefits of implementing Devices and Apps in clinical trials are increased data quality, increased patient compliance/adherence, decreased study timeline, and reduced sample sizes and operation cost ( Figure 13 ). One vendor reported an estimate of 30% to 40% cost savings for sponsors. Another indicated that with just 2% of total trial cost, sponsors will have access to a patient's sleep and activity data throughout the course of a trial. Some vendors reported that in the next 3 years, they will be focusing on system integration, data analytics, and patient engagement. Conversely, site training, device management, site IT support, data file size, and Wi-Fi connectivity have been reported as key challenges encountered by Device and App providers.
Electronic Health Records (EHRs)
Ongoing efforts in the health care industry to enhance patient safety, patient-centric approaches and outcomes, and operational efficiency, coupled with global government-led eHealth initiatives, 4 have made EHR systems increasingly pervasive in clinical practices. This creates an opportunity to leverage the data contained within these systems to support clinical research.
EHR Literature Review
Though EHRs are recognized as being key to leveraging existing patient health information, a scalable path to interoperability between EHR and clinical research systems is still unclear. Scalable solutions for interoperability are being investigated globally by groups composed of overlapping organizations and individuals, and their success is still unknown. The consensus is that scalable interoperability is still in the future.
Current data interoperability efforts include (but not limited to) CDISC eSource Stakeholders Group 12 HL7 FHIR connectathons 13 Demonstration projects proposed within the clinical research community (many with FDA involvement/ sponsorship) 14 EHR4CR (Electronic Health Records for Clinical Systems)/IMI (Innovative Medicines Initiative) 15 The 21st Century Cures Act recently was signed into United States law and includes strong health data privacy protection while permitting sharing of health data with both patients and providers. Russell Branzell, The College of Healthcare Information Management (CHIME) President and CEO, notes that "the law reflects the growing need to develop a standards-based information exchange infrastructure" and that the Act will help create a path for greater interoperability. 16 Variation in EHR vendors and their system implementation and data models introduce a significant challenge to interoperability. Different software versions and EHR capabilities may exist even within the same hospital network.
In 2014, two studies showed that less than half of US hospitals can transmit a patient care document and only 14% of physicians can exchange patient data with outside hospitals or other providers. 17 While vendors have created functionality within their products to enable data exchange, ease of data sharing between EHRs remains a challenge.
EHR Interviews
We interviewed 5 EHR data providers working globally on solutions geared toward enabling EHR for clinical practice and clinical trial research. All vendors had some internal means of querying the existing EHR(s) for patient identification. This is the foundational technical capability for leveraging EHRs for potential clinical research purposes. Approaches and solutions of 4 of 5 vendors include identifying potential patients for clinical trials and current clinical trial participants within their EHR, and identifying basic trial information such as consent date, consent document, or screening information. The remaining EHR vendor is only focused on offering the EHR as a software service. They do not work with any clinical trials, but analyze data for internal purposes or for reporting required by payers for accreditation and/or quality measurement purposes. Although this EHR vendor is not currently offering services for clinical trial research, their ability to analyze data could potentially support such services in the future. Interoperability is being addressed by EHR vendors: Two large US EHR vendors have integrated functionalities to link to EDC systems by leveraging FHIR, enabling users to surface clinical trial forms within the EHR and exchange data between systems.
All vendors identified the same current challenges in leveraging EHR in clinical trials:
Clinical research is only a small part of what EHR users do: EHR systems are rarely proactively implemented with clinical research in mind. Research-specific functionalities are generally not high priority on a hospital's informatics roadmap. There are multiple EHR technologies and designs, as well as many different implementation-specific functionalities. This generates interoperability challenges within and across EHR and EDC systems. Some data elements (eg, demographics, lab values) are reliable and accurate, and are readily available for use in clinical research. However, other variables (eg, clinical findings, certain diagnosis) may require additional review and confirmation. A large portion of the data relevant to clinical research is still captured in free text fields in EHR systems, making it challenging to locate and extract. Solutions based on natural language processing (NLP) are being explored. However, variability of data extraction by NLP software remains an issue. EHR vendors are working to homogenize variability in the common data elements and analytic capabilities of the EHRs to better support analysis for clinical trial research. Integrations between EHR and EDC systems tend to be with EDC systems that are prominent in academia rather than those used in the pharmaceutical industry. Pharmaceutical industry-wide lack of engagement in advancing to eSource (eg, sponsoring pragmatic trials, encouraging EDC vendors to support integrations with EHRs, and committing to use these integrations).
Electronic medical records are inherently developed for clinical practice and can be limited to the setting(s) for which they are developed. An EHR is meant to be a broader health record that is more comprehensive beyond that setting of care. As some of the EHRs, especially in Europe, are quite fragmented and/or built for a specific area of care (eg, hospital only, or ambulatory setting), getting a truly comprehensive view of a patient's care, for clinical practice and especially clinical trials research, can be challenging. This is especially true for global trials or pan-continental studies such as those across Europe, as the EHR solution would have to seamlessly integrate data from multiple health care settings, systems, and sources.
In Europe, an IMI and EFPIA funded project called EHR4CR has involved academic, private, and pharmaceutical industry partners in multiple European countries. The aim of this partnership is to provide adaptable, reusable, and scalable solutions for reusing data from EHRs for clinical research. Compliance with data protection and patient rights legislation in Europe were particular focuses of the project. The focuses of these services are on determining protocol feasibility, patient recruitment, clinical trial execution, and adverse event reporting across multiple therapeutic areas. 15 The EHR4CR initiative is currently in a pilot phase where 10 hospitals across Europe are contributing live data and will be looking to broaden this with more hospitals across Europe.
A survey conducted by researchers affiliated with Canada Health Infoway showed that most Canadian health care professionals have positive experiences with information sharing (about half accessed data electronically) specifically related to obtaining information, ensuring accuracy, and efficiency. There is an expectation that benefits will become more notable over time, as adoption grows and users gain experience combined with functionalities or improvements in systems and workflows (that adapt to user needs). 18 
Discussion
To be interoperable, systems need to be able to exchange data and retain the structure and meaning of the data in the process. The underlying technologies needed to share data among systems are readily available and mature. Software vendors have the opportunity to adapt their systems to appropriately accept and deliver health care and clinical research data to facilitate the process.
Standards can be further categorized as transmission standards and content standards. Transmission standards such as the CDISC Operational Data Model are widely used in clinical research. HL7's new FHIR standard is beginning to be adopted, but broad use of standards is needed to facilitate and expand interoperability. 19 Content standards for research and for health care are commonly used for data collection. Appropriate or adapted standards are needed for data that can be captured via devices and apps.
CDISC promulgates clinical research standards that may be used in conjunction with standards in the broader health care ecosystem and thus may add value for clinical researchers, health care providers, and patients. A seamless flow of data among researchers and practitioners will become the foundation for a learning health care system. 20 Finally, a standard method to uniquely identify patients would strongly contribute to a truly interoperable health care and research ecosystem. The identifier must be globally unique across trials, sponsors, and countries, and the method must also ensure privacy. Today, without a unique patient identifier, there is a greater risk that duplicate patients exist in various systems, data are attributed to a patient in error, or that data may be exposed to the wrong patient, breaching the privacy of another. The ONC Health IT in 2014 estimated error rate is 10% to 20% within health care entities, and 50% to 60% when entities exchange information. 21 The use of standards, including unique identifiers, will help with interoperability to enable use of data from EHR, apps, wearables, etc. in clinical trial research. This topic will be further addressed in the subsequent work done by the TransCelerate eSource Initiative.
Non-CRF Data
Many vendors that handle Non-CRF data do not perceive themselves as being eSource providers. The authors of this paper think that this may have been one of the main reasons why we had few vendors return the technology survey.
Interoperability is lacking for exchanging Non-CRF data with vendors and clients. Currently, there is a mismatch between standards used by the pharmaceutical industry and Non-CRF vendors, for example, Logical Observation Identifiers Names and Codes (LOINC), that provide service to this industry. This makes it difficult for these systems to interact with each other without manual intervention. Furthermore, users must learn several different systems to be able to review and create reports for Non-CRF data.
Efforts to increase operational excellence (eg, reduce patient impact, increase data quality, automate process where possible, utilize data standards, reduce cost) would have a positive impact on clinical research. Many efforts have been put forth to drive laboratory standards. CDISC version one of LAB was released in 2003. In 2003 the US Department of Health and Human Services mandated that all federal agencies should adopt laboratory LOINC to standardize electronic interchange of laboratory results. 22 However, there are many types of nonlaboratory measurements categorized as Non-CRF data that are not addressed by LOINC (eg, imaging tumor measurements, sleep measurements [polysomnography]). CDISC standards for these types of nonlaboratory measurements could be used but are not consistently applied. Digital Imaging and Communications in Medicine is a standard for handling, storing, printing, and transmitting information in medical imaging, and includes a file format definition and a network communications protocol. 23 There is a need to have standards to reduce file format transformation from vendors and sponsors and also help software vendors design standardized systems. This may be the main reason why, in 2017, we still face challenges with exchanging and reconciling Non-CRF data more efficiently.
Direct Data Capture
The industry has made a major transition from paper to electronic CRFs for data collection over the past decade. Logically, sponsors would seek to leverage their considerable investments in EDC platforms as they move toward eSource data collection. As discussed in our previous paper, 1 exploratory efforts have been made by sponsors in recent years to use both existing EDC systems and newer tablet-based systems for DDC; most companies plan additional use of these platforms in the near future.
As indicated by our vendor discussions and survey results, vendors continue to refine existing products, develop new products, and improve interoperability across the wide range of existing and potential future technology solutions. While FDA has encouraged sponsors to utilize eSource technologies to optimize the clinical research process, 2 other health authorities may define eSource differently and may be more cautious because of concerns regarding ICH requirements for Investigator control of source documents, and varying patient privacy and protection laws.
Technology vendors are making considerable innovative efforts to address sponsor, site, patient, and health authority stakeholder concerns. As with any new technology, there will be a period of adjustment and learning for all stakeholders as vendors add product features, address regulatory considerations, and ensure that their products are compliant with developing standards and interoperability initiatives.
Devices and Apps
Currently, data collected using Devices and Apps can be categorized as either validated electronic clinical outcome assessment (eCOA) and/or medical device data collected from a fully validated eSource system, or exploratory data collected directly from patients in bring your own device (BYOD) fashion. Since our technology survey did not separate the two, we suspect that a large proportion of the 2000þ trials using Devices and Apps reflects the maturity and broad adoption of eCOA. Notably, Oncology, Neuroscience, and Respiratory were the top 3 therapeutic areas actively using Devices and Apps for eSource data. The high adoption rate of Devices and Apps in Oncology and Respiratory trials was somewhat unexpected as they have historically depended on the survival rate, tumor imaging, and the exacerbation rate as the primary and secondary endpoints for drug approval. On the other hand, Neuroscience often involves many rating scales and exploratory sensors in the trial design. Consistent with our expectation, Neuroscience has the highest adoption rate of Devices and Apps in clinical trials as well as regulatory submission.
Many sponsors are embracing the concept of patientcentric clinical trials 24 in which the frequency of clinical visits may be reduced through strategic use of Devices and Apps; thereby real-time and real-world data can be captured and recall errors or white-coat syndromes 25 can be avoided. However, this new mode of data collection, bypassing the traditional site-centric eCRF approach, requires secure data flows, data standards, system validation, as well as site and health authority acceptance. Based on our technology survey, the key challenges observed are the lack of validated, interoperable, and secure systems.
When the data are collected by site(s), site personnel follow established practices to ensure the source data are maintained at the site(s) and the data lineage is clear and auditable. Similarly, when eCOA devices are used, vendors centrally manage the entire operation. The eCOA devices are controlled and deployed to sites such that the entire data flow between site(s) and sponsor can be validated. 26 However, the data flow involved in the BYOD scenario can vary widely depending on the cellular network and the devices being used. In the BYOD scenario where screen size, operating systems, applications, devices, and midtrial upgrades are all different, comprehensive system validation is more challenging. 27 Yet, if the industry is to move toward offering a patient-centric trial experience, then the industry, regulators, and technology vendors will need to work out an acceptable solution to overcome the challenge of system validation such as SMART on FHIR. 28 Sponsors as well as technology vendors are interested in the interoperability of various devices and apps and data management systems. 29, 30 A key question is, which devices and apps should be integrated into the data management system? Unfortunately, the industry currently is challenged by the multitude and evolution of devices and apps on the market. Use in clinical trials is possible but remains limited because of a lack of endpoint developments. More collaboration is needed among stakeholders who have shared interest of novel endpoints to develop new measurements that may become primary endpoints intended for regulatory submission.
Finally, while we embrace the potential benefits of eSource, we should be aware of the increasing risks associated with digital connectivity. Based on a report by Symantec, health care was ranked as the sector with the highest (37%) incidence of cyber-attack in 2015. 31 When considering technology, there must be robust data security procedures in place to ensure subject data are protected at the database and device levels. 19, 32, 33 
Electronic Health Records
Key requirements for the efficient and scalable use of EHR data as eSource include EHR compliance with applicable regulations and guidance-including clinical research regulations in addition to health care-related regulations-greater interoperability between EHR systems and interoperability between EHR and clinical research systems. Our literature review as well as stakeholder discussions highlighted interest and activities around interoperability and connectivity, including a broad range of benefits inclusive of patients' access to their health care data and clinical research; however, there is no clear path toward broad interoperability. There still seems to be a lack of consensus among the stakeholders and across regions as to whether governments should be mandating interoperability and related standards, or whether the normal forces of the health care ecosystem will achieve the desired results. 34 Initial attempts at leveraging EHR data for clinical research have revealed that a significant proportion of EHR data are stored in unstructured text fields, or even scanned images of paper records, which do not easily lend themselves to mapping across systems. This constitutes a substantial obstacle to interoperability, both across EHRs and between EHRs and clinical research systems. Currently, data stored in unstructured EHR fields or images of paper records cannot be accessed unless data are extracted and curated, as various data curators that are starting to emerge in this field will do. 35 FDA is collaborating with at least some of these data curators; for example, to help gain "new insights into the safety and effectiveness of emerging anti-cancer therapies." 36 
Conclusion
Survey results show that EDC and DDC technology vendors are engaged with the clinical research community. EDC and DDC vendors are well aware of sponsor interest in eSource and the inevitable adoption that will follow. The technology is mature, deployed globally, and compliant with health authority requirements. Consequently, these systems are being more widely used and vendors are prepared for even broader adoption.
Non-CRF vendors have been providing eSource data for many years. While technology vendors in this arena consider laboratory service providers as their primary customers, they rarely interact directly with sponsors who need to consume the data from their systems for clinical research use. As a result, the integration of Non-CRF data with CRF data is not as streamlined as intended.
Greater engagement between sponsors and Non-CRF technology vendors will be needed to develop more streamlined data flows, improve interoperability with sponsor systems, and modernize data interfaces. Potential benefits include increased data quality, fewer missing patient assessments, and contemporaneous review of patient data.
Devices and Apps are no longer novel. Increasingly, sponsors are using these tools to collect patient data and develop innovative trials. The popularity of these devices has created a fragmented industry. With the exception of a small group, most Device and Apps vendors are consumer-oriented and their products have rarely, or never, been used in clinical research.
Some are starting to see an opportunity in clinical research as sponsors look for Devices and Apps to support research. However, the Devices and Apps technology community is not closely connected to the clinical research community.
Finally, EHR vendors are starting to position their tools in a way that improve support for clinical research. Standards such as FHIR are evolving and organizations such as HL7 may use programming interfaces developed with FHIR to access data in EHR repositories. Meaningful Use 37,38 is providing incentive to promote EHR adoption and enable the exchange of health care information. Legislation such as the "21st Century Cures Act" would further promote a secure interoperable framework for the exchange of health care data. TransCelerate received no responses to the technology survey from EHR vendors. This is likely due to the fact that clinical research sponsors are not the primary customers for EHR vendors and, until recently, have had minimal interaction with this segment of the health care environment. Clinical research/health care communities need to work together to develop data standards and an approach to data exchange. Standards development organizations, regulatory and health care agencies, sites, and patient groups all need to be engaged. The next step of the TransCelerate eSource Initiative will be multifaceted, including development of a framework that lays out steps needed to enable broader use of eSource, engaging in demonstration projects and increasing our focus on collaborative efforts that will move beyond the current landscape. solutions designed to drive the efficient, effective, and high-quality delivery of new medicines. The authors also thank HL7, CDISC, Health Canada, EMA, and FDA for their review of the draft manuscript.
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